Varicella zoster immunity loss in multiple sclerosis patient treated with ocrelizumab

Varicella zoster immunity loss in multiple sclerosis patient treated with ocrelizumab

Copyright © 2020 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 223(2021) vom: 15. Feb., Seite 108554
1. Verfasser: Rapisarda, L (VerfasserIn)
Weitere Verfasser: Valentino, P, Barone, S, Torti, C, La Gamba, V, Fortunato, F, Sammarra, I, Gambardella, A
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Case Reports Journal Article Immunity Multiple sclerosis Ocrelizumab Varicella zoster Anti-Inflammatory Agents Antibodies, Monoclonal, Humanized Antigens, CD20 ocrelizumab A10SJL62JY
Beschreibung
Zusammenfassung:Copyright © 2020 Elsevier Inc. All rights reserved.
Ocrelizumab is a novel humanized anti-CD20 antibody used for treatment of relapsing remitting and primary progressive multiple sclerosis with evidence of inflammatory activity. Guidelines suggest assessing vaccination status and eventually vaccinate patients with multiple sclerosis before new disease modifying therapy initiation. However, there are not any specific recommendations about vaccinal immunity reassessment after ocrelizumab injection. We describe the case of a patient who loss varicella zoster vaccinal immunity after the first ocrelizumab infusion. It is advisable to reassess vaccinal immunity to isolate non-immune patients and to adopt suitable preventive measures, including close contacts vaccination and avoidance of contacts with active infection
Beschreibung:Date Completed 14.06.2021
Date Revised 04.12.2021
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2020.108554